Mal- (CH2) 5-Val-Cit-PAB-Eribulin

Mal- (CH2) 5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal- (CH2) 5-Val-Cit-PAB[1].

Product Specifications

CAS Number

[2130869-21-3]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mal-ch2-5-val-cit-pab-eribulin.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C=C1C[C@](O[C@@]1([H])CC[C@](C[C@H]2C)([H])O[C@](C2=C)([H])C[C@@](O[C@@H]3C[C@H](O)CNC(OCC(C=C4)=CC=C4NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C5=O)C(C=C5)=O)=O)=O)=O)=O)([H])[C@]([C@H]3OC)([H])CC6=O)([H])CC[C@@]7(C[C@@]8([H])O9)O[C@]([C@](O[C@](C6)([H])CC%10)([H])[C@@]%10([H])O%11)([H])[C@@]9([H])[C@]%11([H])[C@@]8([H])O7

Molecular Formula

C69H97N7O19

Molecular Weight

1328.54

References & Citations

[1]Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. Patent US20170252458A1.|[2]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.